Company Overview
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
Why Investors Should Care
Operating margin of 15.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.29.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $28.59M (+39.0% YoY); net profit $-443.15M.
- Trailing 12 Months Year-on-year growth — revenue +52.6%, earnings +125.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -37.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -37.68% |
| 1 Year: | 52.60% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 125.60% |
Stock Price Performance
| 1 Year: | +106.03% |
| 6 Months: | +75.24% |
| 3 Months: | +100.71% |
| 1 Month: | +7.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.03 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -37.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OSCR Oscar Health, Inc. R2K | 31.07 | -57.54 | $8.26B | 0.00% | -27.10% | -2.62% | -37.68% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 341.00K | 353.00K | 1.55M | 18.49M | 20.45M | 19.42M | 5.00M | 5.08M | 5.54M | 5.63M | 5.23M | 4.90M | 4.33M | 6.50M | 8.80M | 5.72M |
| Operating Income | -95.95M | -39.35M | -80.13M | -64.04M | -72.51M | -211.68M | -68.53M | -106.49M | -192.37M | -25.36M | -6.53M | -58.24M | 185.56M | 67.81M | -48.37M | 297.12M | -230.48M | -129.25M | 704.09M |
| Net Income | -96.88M | -40.94M | -79.13M | -88.88M | -73.32M | -211.48M | -75.15M | -112.16M | -192.91M | -39.77M | -15.53M | -65.40M | 177.37M | 56.21M | -54.60M | 275.27M | -228.36M | -137.45M | 679.00M |
| Diluted EPS | -3.36 | -1.42 | -2.72 | -1.00 | -0.35 | -1.02 | -0.36 | -0.53 | -0.91 | -0.18 | -0.07 | -0.29 | 0.62 | 0.20 | -0.22 | 0.92 | -0.89 | -0.53 | 2.07 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 488.19M | 0 | 5.39M | 64.93M | 21.35M | 20.58M | 28.59M |
| Operating Income | -259.39M | -402.27M | -544.48M | -589.87M | -235.62M | 57.27M | -396.36M |
| Net Income | -261.18M | -406.82M | -572.61M | -606.27M | -270.73M | 25.43M | -443.15M |
| Diluted EPS | -9.06 | -14.16 | -3.20 | -2.85 | -1.22 | 0.10 | -1.69 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.27B | 3.32B | 4.53B | 3.60B | 4.84B | 6.33B |
| Total Equity | 0 | -1.30B | 1.39B | 890.38M | 803.97M | 1.01B | 977.65M |
| Cash & Equivalents | 336.64M | 826.33M | 1.10B | 1.56B | 1.87B | 1.53B | 2.77B |
| Long Term Debt | - | 142.49M | 0 | 298.00M | 298.78M | 299.56M | 430.10M |
| Total Liabilities | - | 1.82B | 1.93B | 3.63B | 2.80B | 3.82B | 5.34B |
| Current Liabilities | - | 1.67B | 1.85B | 3.26B | 2.43B | 3.46B | 4.86B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -165.37M | 222.73M | -181.75M | 380.35M | -272.16M | 978.19M | 1.09B |
| Investing Cash Flow | 150.51M | -344.71M | -774.51M | -226.52M | 577.19M | -1.39B | -241.06M |
| Financing Cash Flow | -2.12M | 611.71M | 1.24B | 301.11M | 6.45M | 68.39M | 399.21M |
| Share Buybacks | 2.99M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -53.1% | - | -10,094.2% | -908.5% | -1,103.4% | 278.3% | -1,386.2% |
| Net Margin % | -53.5% | - | -10,615.6% | -933.8% | -1,267.9% | 123.6% | -1,549.9% |
| ROE % | - | 31.4% | -41.3% | -68.1% | -33.7% | 2.5% | -45.3% |
| ROCE % | - | -66.3% | -37.1% | -46.7% | -20.1% | 4.2% | -27.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.51% | 17.31M | $540.58M |
| 2 | T. Rowe Price Investment Management, Inc. | 4.38% | 11.64M | $363.66M |
| 3 | Vanguard Capital Management LLC | 4.05% | 10.78M | $336.59M |
| 4 | Vanguard Portfolio Management LLC | 3.97% | 10.55M | $329.35M |
| 5 | American Century Companies Inc | 2.64% | 7.03M | $219.53M |
| 6 | Thrive Capital Management, LLC | 2.39% | 6.34M | $198.11M |
| 7 | BIT Capital GmbH | 2.38% | 6.32M | $197.42M |
| 8 | Shaw D.E. & Co., Inc. | 2.06% | 5.49M | $171.31M |
| 9 | State Street Corporation | 1.98% | 5.26M | $164.34M |
| 10 | Geode Capital Management, LLC | 1.89% | 5.03M | $157.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OSCR
Oscar Health Stock Is Up 100% and Wall Street Is Finally Starting to Take Notice - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPRzRTajUyZFYweW5DczNwUnBkUkh4N2l6aVZVSWYyQUoxMFc5cXpGVXBkbEtZRkVmdElPTjc3QUktZXk4UmxYbkcwZkx2NjIyTmlxQm40eU9PeWpNSHB2aWxrNWN2YzhOLVNlS2ZfVGxiaVIwajVJdE01N2M0VU1jQ0o3Zm9lOXJOZWxiT3…
Oscar Health (OSCR): A High Growth Momentum Stock Meeting Mark Minervini's Trend Template - ChartMill
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNSzdnZ25fT0ZGVXdTTGxyZWxZSVhCMmFBQ1JiWHdHdlM3Q2N0Ri1GWGxQMVNHYWMyd3V2cmRfY2F0WkQ0bUtoSks0ZVlqdnJ3OXlCUEQ1VHEwdXJkQUU4N0lDNFBZR3Q0TUd0QjlrWElualpTWG1Udi04Rkl3SDFMakNhTzZ6Z2JmN0prZn…
Why Is OSCR Stock Rising Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPSmtBQUJ3WXlnVTBTNWpDODZFVW96OTl4UXIwZm10SHBQOF9uUFh2MEExb0QyeHdfRHFFNkEzR2ZqRWpYSk4xRHVEbUpKcUZIaWFlQnc1c2x0ZDFMMC1tN1lsejBFbXcwcEpwZUNlZGZKbU4xQVpUTFFMVHJGZ0lwVC03UDd2OUFFNkhYM3…
Oscar Health, Inc. (OSCR) Stock Analysis: Evaluating Growth Potential Amidst a Robust 52.60% Revenue Surge - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNS3FHamN0cU1oenI0dFB2aXEzTm0zc1hwZkZpMmN2QUR3NWVQUndRd2JrQTU1TVpDLTJBMjd6YTlaUVc1M214MTF2OEo4ZXJGV25QUWJlMHlPXzZZR2JtREtOWGVYbW9zRXNRZXA1eFJZU2t3TkI1dVRJY0dqMklaMkJ5YTZDb0hLZU1Lan…
Oscar Health (OSCR) director Sid Sankaran receives 858 deferred stock units in lieu of cash - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOeDh3VEJiZVV2enZobk16V29obXhQQnVtUUZ4d1hGMkt3Q3pPRllHdVZiNE1JQmNES2RpYjJRb3pRVjNqQy1GclBIYWlGTGFXWlVJZHBHYWJZdDZpd3dWcjJ3dzBHMmJoTEJ5dWxmTVlnMlBzd2M1X2QybzJ6QUw0WG01ZGFKYW1jSmVrTV…
Oscar Health Inc (OSCR) Shares Surge 3.5% -- What GF Score of 80 Tells Investors - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbWxuQWZjOUtaa3NnbXFVYTJyRnBtdHZEV3cxSDBCQ0xqWE02Y3h5OEZHNm5HMzhDUndzUFJIWFd3U1NqckhXVkt3ZTBFZE04WW5SS0ZnbkNmT3FRMlBzQi1Xd2tHRmNOTWZuSzZaNEdCNmc2OGtLdlo1MDdLcUlCZW9YWWNkR2E3b2dybW…
OSCR — Frequently Asked Questions
What is the current share price of Oscar Health, Inc. (OSCR)?
As of 2026-07-14 21:23 PDT, Oscar Health, Inc. (OSCR) trades at $31.07 on NYSE. Its 52-week range is $10.85 to $32.18.
What is the market capitalisation of OSCR?
Oscar Health, Inc. (OSCR) has a market capitalisation of $8.26B on NYSE.
What is the P/E ratio of OSCR?
OSCR trades at a trailing price-to-earnings (P/E) ratio of -57.54. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.08.
What is the return on equity (ROE) of OSCR?
OSCR has a return on equity (ROE) of -2.62%. Its return on capital employed (ROCE) is -27.10%.
Is OSCR a good stock to buy?
This page provides a data-driven analysis of Oscar Health, Inc. (OSCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.